152 related articles for article (PubMed ID: 33386423)
1. A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers.
Chen R; Wang H; Zhong W; Chessari S; Lanzarotti C; Bernareggi A; Hu P
Cancer Chemother Pharmacol; 2021 Mar; 87(3):387-396. PubMed ID: 33386423
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Kurteva G; Chilingirova N; Rizzi G; Caccia T; Stella V; Bernareggi A
Eur J Pharm Sci; 2019 Nov; 139():105041. PubMed ID: 31404621
[TBL] [Abstract][Full Text] [Related]
3. Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.
Calcagnile S; Lanzarotti C; Rossi G; Henriksson A; Kammerer KP; Timmer W
Support Care Cancer; 2013 Oct; 21(10):2879-87. PubMed ID: 23748441
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open-label, crossover phase 1 study.
Calcagnile S; Lanzarotti C; Gutacker M; Jakob-Rodamer V; Peter Kammerer K; Timmer W
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):377-86. PubMed ID: 27137147
[TBL] [Abstract][Full Text] [Related]
5. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S
Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643
[TBL] [Abstract][Full Text] [Related]
7. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
[TBL] [Abstract][Full Text] [Related]
8. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
[TBL] [Abstract][Full Text] [Related]
9. Netupitant PET imaging and ADME studies in humans.
Spinelli T; Calcagnile S; Giuliano C; Rossi G; Lanzarotti C; Mair S; Stevens L; Nisbet I
J Clin Pharmacol; 2014 Jan; 54(1):97-108. PubMed ID: 24122871
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Hesketh PJ; Rossi G; Rizzi G; Palmas M; Alyasova A; Bondarenko I; Lisyanskaya A; Gralla RJ
Ann Oncol; 2014 Jul; 25(7):1340-1346. PubMed ID: 24608196
[TBL] [Abstract][Full Text] [Related]
11. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
Lorusso V; Karthaus M; Aapro M
Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
[TBL] [Abstract][Full Text] [Related]
12. Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Gilmore J; Bernareggi A
J Clin Pharmacol; 2019 Apr; 59(4):472-487. PubMed ID: 30412271
[TBL] [Abstract][Full Text] [Related]
13. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H
Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.
Natale JJ; Spinelli T; Calcagnile S; Lanzarotti C; Rossi G; Cox D; Kashef K
J Oncol Pharm Pract; 2016 Jun; 22(3):485-95. PubMed ID: 25998320
[TBL] [Abstract][Full Text] [Related]
15. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
[TBL] [Abstract][Full Text] [Related]
16. Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Keating GM
Drugs; 2015 Dec; 75(18):2131-41. PubMed ID: 26613606
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
Rugo HS; Rossi G; Rizzi G; Aapro M
Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
[TBL] [Abstract][Full Text] [Related]
18. Capsule-related dysphagia and the use of netupitant/palonosetron (Akynzeo™) capsules - A report of two cases and a solution.
Behbahany K; Bubalo J
J Oncol Pharm Pract; 2021 Jul; 27(5):1284-1286. PubMed ID: 33100182
[TBL] [Abstract][Full Text] [Related]
19. Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
Darmani NA; Zhong W; Chebolu S; Mercadante F
Pharmacol Biochem Behav; 2015 Apr; 131():104-11. PubMed ID: 25687374
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.
Tyler T; Schultz A; Venturini A; Giuliano C; Bernareggi A; Spezia R; Voisin D; Stella V
Clin Pharmacol Drug Dev; 2022 Dec; 11(12):1405-1418. PubMed ID: 36263927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
